Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study
|
|
- Elmer Young
- 5 years ago
- Views:
Transcription
1 Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Hidenori Arai 1, Yoshihiro Kokubo 2, Makoto Watanabe 2, Tatsuya Sawamura 3, Tomonori Okamura 4, and Yoshihiro Miyamato 2 1 Department of Human Health Sciences, Kyoto University Graduate School of Medicine 2 Department of Preventive Cardiology, 3 Department of Vascular Physiology, National Cerebral and Cardiovascular Center 4 Department of Preventive Medicine and Public Health, School of Medicine, Keio University
2 Abstract Background and aim: Increased plasma low-density lipoprotein (LDL) cholesterol (LDL-C) concentrations have been shown to be a significant risk factor for coronary artery disease (CAD). Clinical evidence also indicated that small dense LDL (sd-ldl) particles are more atherogenic than large buoyant LDL particles. Because there was no easy assay to measure the amount of sd-ldl, no study has addressed the association between sd-ldl and cardiovascular disease. Therefore, we examined the association between sd-ldl cholesterol (sd-ldl-c) and CAD using a new assay kit for sd-ldl-c in an urban Japanese cohort. Methods: The Suita study is an 11.7-year prospective study in an urban population aged without history of myocardial infarction or stroke. Direct LDL-C and sd-ldl-c were measured in samples from 2034 participants (968 men and 1066 women) by a kit based on the precipitation method with filtration. We calculated the multivariable-adjusted hazard ratios (HRs) of sd-ldl-c and sd-ldl/ldl ratio for CAD using a proportional hazards regression model after adjusting for age, sex, hypertension, diabetes, use of lipid lowering agent, body mass index (BMI), current smoking, and alcohol drinking. Results: We divided men and women to 4 groups according to the quartiles of sd-ldl-c. Levels of sd-ldl-c were positively associated with total cholesterol, triglyceride, BMI, blood pressure, and were negatively correlated with HDL-cholesterol both in men and women. Levels of sd-ldl-c were positively correlated with age only in women. After adjusting age and sex, increasing quartiles of sd-ldl-c were associated with increased incidence of CAD (p=0.001). The HR of the 4th quartile was 3.35 (95% confidence intervals [95% CI]: ). In multivariable adjustment, the HR of the 4th quartile was almost similar. Sex-specific analysis showed that the association between sd-ldl-c and CAD was statistically significant in men, but not in women. We also found that sd- LDL/LDL ratio was a significant risk for CAD after age and sex- and multivariable-adjustment (p=0.001, 0.005, respectively). Furthermore, higher sd-ldl/ldl ratios were significantly associated with CAD even after LDL-C adjustment. Conclusions: We demonstrated that sd-ldl-c and sd-ldl/ldl are significantly associated with the development of CAD in Japanese without history of myocardial infarction or stroke. Our data indicate that sd-ldl-c is an independent and new risk factor for CAD and should be incorporated for a risk assessment. However, a larger study should be done to show the role of sd-ldl on CAD in women.
3 Background Compared to large, buoyant LDL, small dense LDL (sd-ldl) particles exhibit a prolonged plasma residence time, increased penetration into the arterial wall, lower affinity for the LDL receptor, and increased susceptibility to oxidation. Thus, sd-ldl particles possess an elevated atherogenic potential. However, few prospective studies have been done to address the role of sd-ldl in the development of cardiovascular disease.
4 Aims Address whether sd-ldl cholesterol can predict the development of CAD in a large cohort study of Japan, the Suita study.
5 Methods The Suita study, a cohort study for CVD of urban residents was established in men and women aged years had a baseline survey at the National Cerebral and Cardiovascular Center between September 1989 and March For the purposes of this study, we used archived plasma samples that had been frozen at 80 o C for the assessment of direct LDL-C and sd-ldl-c by automated standardized enzymatic analysis on a Hitachi 911 automated analyzer. The kits used for these tests (LDL-C and sd-ldl-c) were provided by Denka Seiken, Tokyo, Japan.
6 Principle of the homogeneous assay for sd LDL-C TRL lb-ldl sd-ldl HDL R1 Surfactant A Sphingomyelinase Surfactant B Surfactant A React and Eliminate React and Eliminate Protect React and Eliminate Cholesterol Cholesterol Cholesterol Cholesterol Esterase Cholesterol Oxidase Catalase Cholesterol Esterase Cholesterol Oxidase Catalase 2H 2 O + O 2 2H 2 O + O 2 2H 2 O + O 2 R2 Purple-red color Measurement H 2 O 2 Cholesterol Esterase Cholesterol Oxidase peroxidase Cholesterol sd-ldl
7 Results
8 1. Baseline Characteristic of Cardiovascular Risk Factors According to Small-dense LDL Cholesterol Quartiles in Men Men Small-dense LDL Cholesterol Q1 Q2 Q3 Q4 Number of subjects Small-dence LDL, range (mean), mg/dl (21.1) (32.7) (45.3) (67.3) P value for Trend Age, year 60.9± ± ± ± Body mass index, kg/m^2 21.5± ± ± ±2.7 <0.001 TC, mg/dl 170±25 189±24 199±25 220±27 <0.001 HDL-C, mg/dl 60±15 57±14 51±11 48±11 <0.001 LDL, mg/dl 86±20 111±21 124±23 140±26 <0.001 Large-LDL, mg/dl 65±17 78±21 79±22 72±24 <0.001 Sd-LDL/LDL ratio 0.25± ± ± ±0.11 <0.001 Blood pressure category, % Optimal blood pressure Normal blood pressure High-normal blood pressure Hypertension grade I-III Antilipidemic drug use, % Diabetes, % Current Smoking, % Current Drinking, %
9 2. Baseline Characteristic of Cardiovascular Risk Factors According to Small-dense LDL Cholesterol Quartiles in Women Women Small-dense LDL Cholesterol Q1 Q2 Q3 Q4 Number of subjects Small-dence LDL, range (mean), mg/dl (18.7) (28.6) (38.5) (59.7) P value for Trend Age, year 51.7± ± ± ±9.1 <0.001 Body mass index, kg/m^2 21.0± ± ± ±2.8 <0.001 TC, mg/dl 175±23 200±22 216±25 234±32 <0.001 HDL-C, mg/dl 67±13 64±12 60±13 54±12 <0.001 LDL, mg/dl 83±17 109±17 130±18 153±30 <0.001 Large-LDL, mg/dl 64±14 81±15 92±17 93±25 <0.001 Sd-LDL/LDL ratio 0.23± ± ± ±0.08 <0.001 Blood pressure category, % <0.001 Optimal blood pressure Normal blood pressure High-normal blood pressure Hypertension grade I-III Antilipidemic drug use, % Diabetes, % <0.001 Current Smoking, % Current Drinking, %
10 3. Age- and Multivariate-adjusted Hazard Ratios for the incidence of CVD according to small dense LDL cholesterol quartiles Small dense LDL Cholesterol Q1 (Lower) Q2 Q3 Q4 (Higher) P for trend Men and women Person-years 5,593 5,773 5,597 5,739 Cardiovascular disease Case Age-adjusted ( ) 1.11 ( ) 1.64 ( ) Multivariable-adjusted ( ) 1.08 ( ) 1.60 ( ) Stroke Case Age-adjusted ( ) 0.80 ( ) 1.21 ( ) Multivariable-adjusted ( ) 0.79 ( ) 1.19 ( ) Cerebral infarction Case Age-adjusted ( ) 1.14 ( ) 1.74 ( ) Multivariable-adjusted ( ) 1.16 ( ) 1.85 ( ) Coronary heart disease Case Age-adjusted ( ) 2.26 ( ) 3.35 ( ) Multivariable-adjusted ( ) 2.17 ( ) 3.26 ( ) 0.003
11 4. Age- and Multivariate-adjusted Hazard Ratios for the incidence of CVD according to small dense LDL cholesterol quartiles in men Small dense LDL Cholesterol Q1 (Lower) Q2 Q3 Q4 (Higher) P for trend Men, range Person-years 1,990 2,488 2,457 3,306 Cardiovascular disease Case Age-adjusted ( ) 1.28 ( ) 1.62 ( ) Multivariable-adjusted ( ) 1.32 ( ) 1.85 ( ) Stroke Case Age-adjusted ( ) 0.99 ( ) 1.05 ( ) Multivariable-adjusted ( ) 1.11 ( ) 1.22 ( ) Cerebral infarction Case Age-adjusted ( ) 1.13 ( ) 1.30 ( ) Multivariable-adjusted ( ) 1.18 ( ) 1.43 ( ) Coronary heart disease Case Age-adjusted ( ) 2.28 ( ) 3.50 ( ) Multivariable-adjusted ( ) 2.16 ( ) 3.96 ( ) 0.004
12 5. Age- and Multivariate-adjusted Hazard Ratios for the incidence of CVD according to small dense LDL cholesterol quartiles in women Small dense LDL Cholesterol Q1 (Lower) Q2 Q3 Q4 (Higher) P for trend Women, range Person-years 3,603 3,285 3,140 2,432 Cardiovascular disease Case Age-adjusted ( ) 0.91 ( ) 1.77 ( ) Multivariable-adjusted ( ) 0.80 ( ) 1.41 ( ) Stroke Case Age-adjusted ( ) 0.61 ( ) 1.57 ( ) Multivariable-adjusted ( ) 0.57 ( ) 1.32 ( ) Cerebral infarction Case Age-adjusted ( ) 1.31 ( ) 3.91 ( ) Multivariable-adjusted Coronary heart disease Case Age-adjusted ( ) 2.25 ( ) 2.82 ( ) Multivariable-adjusted
13 6. Age- and Multivariate-adjusted Hazard Ratios for the incidence of CVD according to large dense LDL cholesterol quartiles Large buoyant LDL Q1 (Lower) Q2 Q3 Q4 (Higher) P for trend Men and women Person-years 5,707 5,828 6,053 5,934 Cardiovascular disease Case Age-adjusted ( ) 0.70 ( ) 1.00 ( ) Multivariable-adjusted ( ) 0.73 ( ) 1.01 ( ) Stroke Case Age-adjusted ( ) 0.61 ( ) 0.82 ( ) Multivariable-adjusted ( ) 0.68 ( ) 0.88 ( ) Cerebral infarction Case Age-adjusted ( ) 0.83 ( ) 0.79 ( ) Multivariable-adjusted ( ) 0.91 ( ) 0.83 ( ) Coronary heart disease Case Age-adjusted ( ) 0.83 ( ) 1.31 ( ) Multivariable-adjusted ( ) 0.81 ( ) 1.20 ( ) 0.801
14 7. Age- and Multivariate-adjusted Hazard Ratios for the incidence of CVD according to sdldl/ldl ratio quartiles Ratio of small dense LDL and LDL Cholesterol Q1 (Lower) Q2 Q3 Q4 (Higher) P for trend Men and women Person-years 5,627 5,735 5,646 5,625 Cardiovascular disease Case Age-adjusted ( ) 1.58 ( ) 2.82 ( ) <0.001 Multivariable-adjusted ( ) 1.59 ( ) 2.51 ( ) Stroke Case Age-adjusted ( ) 1.82 ( ) 2.88 ( ) Multivariable-adjusted ( ) 1.81 ( ) 2.46 ( ) Cerebral infarction Case Age-adjusted ( ) 3.02 ( ) 2.96 ( ) Multivariable-adjusted ( ) 2.93 ( ) 2.70 ( ) Coronary heart disease Case Age-adjusted ( ) 1.30 ( ) 2.86 ( ) Multivariable-adjusted ( ) 1.31 ( ) 2.76 ( ) 0.005
15 8. Age- and Multivariate-adjusted Hazard Ratios for the incidence of CVD according to sdldl/ldl ratio quartiles in men Ratio of small dense LDL and LDL Cholesterol Q1 (Lower) Q2 Q3 Q4 (Higher) P for trend Men Person-years 1,885 2,015 2,573 3,768 Cardiovascular disease Case Age-adjusted ( ) 1.46 ( ) 2.28 ( ) Multivariable-adjusted ( ) 1.64 ( ) 2.26 ( ) Stroke Case Age-adjusted ( ) 1.45 ( ) 1.67 ( ) Multivariable-adjusted ( ) 1.64 ( ) 1.64 ( ) Cerebral infarction Case Age-adjusted ( ) 2.06 ( ) 1.53 ( ) Multivariable-adjusted ( ) 2.23 ( ) 1.50 ( ) Coronary heart disease Case Age-adjusted ( ) 1.63 ( ) 4.01 ( ) Multivariable-adjusted ( ) 1.73 ( ) 4.38 ( ) 0.019
16 9. Age- and Multivariate-adjusted Hazard Ratios for the incidence of CVD according to sdldl/ldl ratio quartiles in women Ratio of small dense LDL and LDL Cholesterol Q1 (Lower) Q2 Q3 Q4 (Higher) P for trend Women Person-years 3,742 3,720 3,073 1,857 Cardiovascular disease Case Age-adjusted ( ) 1.71 ( ) 4.18 ( ) Multivariable-adjusted ( ) 1.74 ( ) 3.60 ( ) Stroke Case Age-adjusted ( ) 3.02 ( ) 9.04 ( ) Multivariable-adjusted Cerebral infarction Case Age-adjusted Multivariable-adjusted Coronary heart disease Case Age-adjusted ( ) 1.19 ( ) 2.23 ( ) Multivariable-adjusted ( ) 1.19 ( ) 1.58 ( ) 0.206
17 10. Age- and Multivariate-adjusted Hazard Ratios for the incidence of CVD according to LDL cholesterol quartiles LDL Cholesterol Q1 (Lower) Q2 Q3 Q4 (Higher) P for trend Men and women Person-years 5,591 5,675 5,715 5,684 Cardiovascular disease Case Age-adjusted ( ) 0.82 ( ) 1.34 ( ) Multivariable-adjusted ( ) 0.91 ( ) 1.30 ( ) Stroke Case Age-adjusted ( ) 0.62 ( ) 1.08 ( ) Multivariable-adjusted ( ) 0.71 ( ) 1.12 ( ) Cerebral infarction Case Age-adjusted ( ) 0.96 ( ) 1.11 ( ) Multivariable-adjusted ( ) 1.08 ( ) 1.15 ( ) Coronary heart disease Case Age-adjusted ( ) 1.28 ( ) 1.99 ( ) Multivariable-adjusted ( ) 1.41 ( ) 1.76 ( ) 0.107
18 11. Age- and Multivariate-adjusted Hazard Ratios for the incidence of CVD according to LDL cholesterol quartiles in men LDL Cholesterol Q1 (Lower) Q2 Q3 Q4 (Higher) P for trend Men Person-years 2,561 2,694 2,641 2,377 Cardiovascular disease Case Age-adjusted ( ) 1.08 ( ) 1.66 ( ) Multivariable-adjusted ( ) 1.26 ( ) 1.83 ( ) Stroke Case Age-adjusted ( ) 0.89 ( ) 1.11 ( ) Multivariable-adjusted ( ) 1.17 ( ) 1.42 ( ) Cerebral infarction Case Age-adjusted ( ) 1.10 ( ) 1.08 ( ) Multivariable-adjusted ( ) 1.30 ( ) 1.15 ( ) Coronary heart disease Case Age-adjusted ( ) 1.53 ( ) 2.98 ( ) Multivariable-adjusted ( ) 1.73 ( ) 2.96 ( ) 0.017
19 Summary This study showed an increased risk of CAD attributed to elevated sd-ldl-c concentrations in a Japanese population without previous history of CVD. Sd-LDL-C/LDL-C is also a significant predictor for CAD both in men and women.
20 Conclusions In this large urban cohort study conducted in Japan, we demonstrated that sd-ldl-c and sd-ldl-c/ldl-c are significantly associated with the development of CAD, providing evidence of sd-ldl-c as an important biomarker to predict CAD. A large intervention study is required to address the target goal of sd- LDL-C.
REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING
REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND
More informationLipoprotein Particle Profile
Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular
More informationSupplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups
Supplemental Table S1: Unadjusted and Adjusted Hazard Ratios for Diabetes Associated with Baseline Factors Considered in Model 3 SMART Participants Only Unadjusted Adjusted* Baseline p-value p-value Covariate
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationSmall Dense LDL Cholesterol is a Promising Biomarker for Secondary Prevention
GGI-0624-2017 Small Dense LDL Cholesterol is a Promising Biomarker for Secondary Prevention in Elder Men with Stable Coronary Artery Disease A short running title Small Dense LDL for Secondary Prevention
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationSupplementary information for: A functional variation in BRAP confers risk of myocardial infarction in Asian populations
Supplementary information for: A functional variation in BRAP confers risk of myocardial infarction in Asian populations Kouichi Ozaki 1, Hiroshi Sato 2, Katsumi Inoue 3, Tatsuhiko Tsunoda 4, Yasuhiko
More informationLong-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease
Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationTracking a Killer Molecule
Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationLIPOPROTEIN PROFILING
LIPOPROTEIN PROFILING in CLINICAL DIAGNOSTICS and LIFE SCIENCE RESEARCH Product Information, March 2015 2004-2015, numares HEALTH LIPOPROTEINS AND CARDIOVASCULAR DISEASE High blood cholesterol is a well-known
More informationEstimation of glucose in blood serum
Estimation of glucose in blood serum Enzymatic estimation of glucose uses a reagent containing two enzymes and a chromogen. Glucose oxidase catalyses the oxidation of glucose to gluconolactone with the
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationZEUS Trial ezetimibe Ultrasound Study
Trial The lower, The better Is it True for Plaque Regression? Statin alone versus Combination of Ezetimibe and Statin Juntendo University, Department of Cardiology, Tokyo, Japan Katsumi Miyauchi, Naohisa
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationTHE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES
Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C
More informationDisclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017
Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital
More informationLDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC
Am J Cardiol (2004);94:729-32 Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors M. Y. Desai, et al. Ciccarone Preventive
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationTable S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).
Table S1. Characteristics associated with frequency of nut (full entire sample; Nn=4,416). Daily nut Nn= 212 Weekly nut Nn= 487 Monthly nut Nn= 1,276 Infrequent or never nut Nn= 2,441 Sex; n (%) men 52
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationHIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES
HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused
More informationSUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.
Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not
More informationFigure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
More informationGlycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men:
Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men: The Kuopio Ischaemic Heart Disease Risk Factor Study Jaakko Mursu, Jyrki K. Virtanen, Tiina H. Rissanen,
More informationLipoprotein (a) Disclosures 2/20/2013. Lipoprotein (a): Should We Measure? Should We Treat? Health Diagnostic Laboratory, Inc. No other disclosures
Lipoprotein (a): Should We Measure? Should We Treat? Joseph P. McConnell, Ph.D. DABCC Health Diagnostic Laboratory Inc. Baptist Health South Florida Eleventh Annual Cardiovascular Disease Prevention International
More informationSupplementary Online Content
Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationBCH 447. Triglyceride Determination in Serum
BCH 447 Triglyceride Determination in Serum Introduction: Triglycerides are esters of fatty acids and are hydrolyzed by lipase to glycerol and free fatty acids. Triglyceride determinations when performed
More informationTriglyceride determination
Triglyceride determination Introduction: - Triglycerides are esters of fatty acids and are hydrolyzed to glycerol and free fatty acids (by lipase) - Triglyceride determinations when performed in conjunction
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationMetabolism and Atherogenic Properties of LDL
Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationDepartment of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan. 4
146 Journal of Atherosclerosis and Thrombosis Original Articles Vol. 11, No. 3 Clinical Features of Familial Hypercholesterolemia in Japan in a Database from 1996 1998 by the Research Committee of the
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationsphingotest vr-hgh Risk Prediction of Incident Cardiovascular Disease
sphingotest vr-hgh Risk Prediction of Incident Cardiovascular Disease Human Growth Hormone as Vascular Risk Biomarker sphingotec offers the vascular risk human Growth Hormone biomarker (vr-hgh) for the
More informationPart 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD
Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationBlood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan.
Blood pressure and total cholesterol level are critical risks especially for hemorrhagic stroke in Akita, Japan. Manabu Izumi, Kazuo Suzuki, Tetsuya Sakamoto and Masato Hayashi Jichi Medical University
More informationPlasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationJoint Impact of Smoking and Hypertension on Cardiovascular Disease and All-Cause Mortality in Japan: NIPPON DATA80, a 19-Year Follow-Up
1169 Original Article Hypertens Res Vol.30 (2007) No.12 p.1169-1175 Joint Impact of Smoking and Hypertension on Cardiovascular Disease and All-Cause Mortality in Japan: NIPPON DATA80, a 19-Year Follow-Up
More informationTriglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study
1/5 Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge
More informationLife Science Journal 2018;15(12)
Multicenter observational study of risk factors profile in a sample of Egyptian Patients with Acute Coronary Syndrome (part of Egyptian Cardiovascular Risk Factors Project) Prof. Dr. Ahmed Ashraf Reda,
More informationDeclaration of conflict of interest. Dominique de Kleijn is founder of a UMC Utrecht spin-off biomarker company Cavadis BV
Declaration of conflict of interest Dominique de Kleijn is founder of a UMC Utrecht spin-off biomarker company Cavadis BV BIOMARKERS OF DISEASE Microvesicle proteins as diagnostic and predictive biomarkers
More informationA comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus
Original Research Article A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus Deepa Kalikavil Puthenveedu 1, Sundaraj
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationImpact of Chronicity on Lipid Profile of Type 2 Diabetics
Impact of Chronicity on Lipid Profile of Type 2 Diabetics Singh 1, Gurdeep & Kumar 2, Ashok 1 Ph.D. Research Scholar, Department of Sports Science, Punjabi University Patiala, India, Email: drgurdeep_sahni@yahoo.co.in
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationLipid/Lipoprotein Structure and Metabolism (Overview)
Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationHigh-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU
ESC Congress 2011 Paris, France, August 27-31 KAROLA Session: Prevention: Are biomarkers worth their money? Abstract # 84698 High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients
More informationDysfunctional HDL and Coronary Artery Disease (CAD) UMHS-PUHSC JOINT INSTITUTE
Dysfunctional HDL and Coronary Artery Disease (CAD) UMHS-PUHSC JOINT INSTITUTE PIs and Members of HDL Project Wei Gao, M.D., Ph.D. Professor and Chair Cardiology Third Hospital, PUHSC Yong Huo, M.D., Ph.D.
More informationPLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL
PLASMA LIPOPROTEINS AND LIPIDS DETERMINATION OF PLASMA CHOLESTEROL AND TRIGLICERIDE LEVEL Lipids are characterized by low polarity and limited solubility in water. Their plasma concentration is about 500-600
More informationRace Original cohort Clean cohort HR 95%CI P HR 95%CI P. <8.5 White Black
Appendix Table 1: Hazard Ratios of the association between CSCs and all-cause mortality from original cohort and the clean cohort excluding CHD/strokes. CSC categories Race Original cohort Clean cohort
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationdoi: /j.atherosclerosis
doi: 10.1016/j.atherosclerosis.2012.01.013 Page 1 High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population: the JPHC study Renzhe Cui 1, Hiroyasu Iso 1, Kazumasa
More informationMetabolic Syndrome and Workplace Outcome
Metabolic Syndrome and Workplace Outcome Maine Worksite Wellness Initiative June 15, 2010 Alyssa B. Schultz Dee W. Edington Current Definition* of Metabolic Syndrome At least 3 of the following: Waist
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationKEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers
CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes
More informationCorrelation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.
Correlation of LV Longitudinal Strain by 2D Speckle Tracking with Cardiovascular risk in Elderly. (A pilot study of EGAT-Echo study.) Researcher: Dr. Atthakorn Wutthimanop, MD. Research adviser: Dr.PrinVathesathokit,
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationBIOCHEMISTRY BLOOD - SERUM Result Range Units
BIOCHEMISTRY BLOOD - SERUM Result Range Units LIPIDS CHOLESTEROL 3.9 0.0-5.5 mmol/l TRIGLYCERIDES 0.7 < 1.5 mmol/l LIPID STUDIES HDL(Protective) 1.5 > 1.2 mmol/l LDL(Atherogenic) 2.1 0.5-3.5 mmol/l Cholesterol/HDL
More informationAHA Clinical Science Special Report: November 10, 2015
www.canheart.ca High-density lipoprotein cholesterol and cause-specific mortality: A population-based study of more than 630,000 individuals without prior cardiovascular conditions Dennis T. Ko, MD, MSc;
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationLipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease
Lipid Risk Factors (Novel) in Risk Assessment and Management of Cardiovascular Disease Policy Number: Original Effective Date: MM.02.013 02/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO;
More informationThe Framingham Risk Score (FRS) is widely recommended
C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany Wolfgang Koenig, MD; Hannelore
More informationChapter 18. Diet and Health
Chapter 18 Diet and Health Risk Factors and Chronic Diseases Interrelationships among Chronic Diseases Chronic Disease Heart Disease and Stroke Hypertension Cancer Diabetes The Formation of Plaques in
More informationTest5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight
Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight Quest, Quest Diagnostics, the associated logo, and all associated Quest Diagnostics marks are the registered trademarks of Quest
More informationImpact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography
Impact of Body Mass Index and Metabolic Syndrome on the Characteristics of Coronary Plaques Using Computed Tomography Angiography Cardiovascular Division, Faculty of Medicine, University of Tsukuba Akira
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationElevated serum creatine kinase predicts first-ever myocardial infarction: a 12-year population-based cohort study in Japan, the Suita study
Published by Oxford University Press on behalf of the International Epidemiological Association ß The Author 2009; all rights reserved. Advance Access publication 25 June 2009 International Journal of
More informationEXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION
1 A STUDY ON THE EFFECT OF DIET & LIFE STYLE ON THE INCIDENCE OF CORONARY ARTERY DISEASE IN MODERATELY DRINKING EX MILITARY MEN IN PATHANAMTHITTA DISTRICT. EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationHeart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial
Heart Rate in Patients with Coronary Artery Disease - the Lower the Better? An Analysis from the Treating to New Targets (TNT) trial Sripal Bangalore, MD, MHA, Chuan-Chuan Wun, PhD, David A DeMicco, PharmD,
More informationMeasurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date
MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationMaster Class in Preventive Cardiology. The New MI Phenotype OR. Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden
Master Class in Preventive Cardiology The New MI Phenotype OR Klas Malmberg MD, PhD, FESC Karolinska Institutet, Stockholm Sweden The New MI Phenotype OR Coronary disease and glucose abnormalities Klas
More informationNovel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
Page: 1 of 34 Last Review Status/Date: March 2016 Management of Cardiovascular Disease Description Numerous lipid and nonlipid biomarkers have been proposed as potential risk markers for cardiovascular
More informationRetrospective Cohort Study for the Evaluation of Life- Style Risk Factors in Developing Metabolic Syndrome under the Estimated Abdominal Circumference
Original Asian Pacific Journal of Disease Management 2007; 1(2), 55-63 Retrospective Cohort Study for the Evaluation of Life- Style Risk Factors in Developing Metabolic Syndrome under the Estimated Abdominal
More informationDYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul Rashid
Malaysian Journal of Medical Sciences, Vol. 11, No. 1, January 2004 (44-51) ORIGINAL ARTICLE DYSLIPIDAEMIC PATTERN OF PATIENTS WITH TYPE 2 DIABETES MELLITUS Eid Mohamed, Mafauzy Mohamed*, Faridah Abdul
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More information